JP2007511534A - 抗腫瘍免疫の相乗的誘導のための組成物および方法 - Google Patents
抗腫瘍免疫の相乗的誘導のための組成物および方法 Download PDFInfo
- Publication number
- JP2007511534A JP2007511534A JP2006539955A JP2006539955A JP2007511534A JP 2007511534 A JP2007511534 A JP 2007511534A JP 2006539955 A JP2006539955 A JP 2006539955A JP 2006539955 A JP2006539955 A JP 2006539955A JP 2007511534 A JP2007511534 A JP 2007511534A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor
- acid sequence
- endothelial marker
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005809 anti-tumor immunity Effects 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 101
- 238000000034 method Methods 0.000 title claims description 39
- 230000002195 synergetic effect Effects 0.000 title abstract description 7
- 230000006698 induction Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 149
- 101710125943 Anthrax toxin receptor 1 Proteins 0.000 claims abstract description 141
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims abstract description 141
- 239000000427 antigen Substances 0.000 claims abstract description 72
- 108091007433 antigens Proteins 0.000 claims abstract description 72
- 102000036639 antigens Human genes 0.000 claims abstract description 72
- 229960005486 vaccine Drugs 0.000 claims abstract description 50
- 239000012634 fragment Substances 0.000 claims description 56
- 150000007523 nucleic acids Chemical group 0.000 claims description 51
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 21
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 19
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 18
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 17
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 16
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 16
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 102000003425 Tyrosinase Human genes 0.000 claims description 10
- 108060008724 Tyrosinase Proteins 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000010255 intramuscular injection Methods 0.000 claims description 9
- 239000007927 intramuscular injection Substances 0.000 claims description 9
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 230000005975 antitumor immune response Effects 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 101000796094 Mus musculus Anthrax toxin receptor 1 Proteins 0.000 claims 3
- 108091005461 Nucleic proteins Proteins 0.000 claims 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 abstract description 10
- 238000013459 approach Methods 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 38
- 108010041986 DNA Vaccines Proteins 0.000 description 33
- 229940021995 DNA vaccine Drugs 0.000 description 33
- 238000002649 immunization Methods 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000036039 immunity Effects 0.000 description 17
- 230000028993 immune response Effects 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 8
- 108010039069 anthrax toxin receptors Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 6
- 238000002271 resection Methods 0.000 description 6
- 208000001382 Experimental Melanoma Diseases 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000003606 umbilical vein Anatomy 0.000 description 5
- 206010027458 Metastases to lung Diseases 0.000 description 4
- 101000856426 Mus musculus Cullin-7 Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100162777 Mus musculus Antxr1 gene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 101100501691 Rattus norvegicus Erbb2 gene Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 102000052461 human ANTXR1 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000830183 Homo sapiens tRNA (guanine-N(7)-)-methyltransferase Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 102000046634 human TYRP1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108700033053 mouse PSMA Proteins 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000005005 sentinel lymph node Anatomy 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000010700 sporadic breast cancer Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102100025028 tRNA (guanine-N(7)-)-methyltransferase Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229940038237 tumor antigen vaccine Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51949803P | 2003-11-13 | 2003-11-13 | |
| PCT/US2004/038022 WO2005048943A2 (en) | 2003-11-13 | 2004-11-15 | Compositions and methods for synergistic induction of antitumor immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511534A true JP2007511534A (ja) | 2007-05-10 |
| JP2007511534A5 JP2007511534A5 (https=) | 2008-01-10 |
Family
ID=34619349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539955A Pending JP2007511534A (ja) | 2003-11-13 | 2004-11-15 | 抗腫瘍免疫の相乗的誘導のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080171058A1 (https=) |
| EP (1) | EP1687432A4 (https=) |
| JP (1) | JP2007511534A (https=) |
| WO (1) | WO2005048943A2 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016208988A (ja) * | 2010-10-19 | 2016-12-15 | メリアル インコーポレイテッド | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン |
| JP2017522326A (ja) * | 2014-07-18 | 2017-08-10 | ユニヴァーシティ オブ ワシントン | がんワクチン組成物およびその使用方法 |
| JP7256024B2 (ja) | 2013-03-15 | 2023-04-11 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ガンワクチン及びそれを用いた治療方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007227208A1 (en) * | 2006-03-23 | 2007-09-27 | Sloan-Kettering Institute For Cancer Research | TEM8 as an adjuvant and uses thereof |
| ITRM20060337A1 (it) * | 2006-06-27 | 2007-12-28 | Biosoot Srl | Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici |
| TW201425333A (zh) * | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| CN101113179B (zh) * | 2007-06-22 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种基于肿瘤内皮细胞标志物8的人源抗体样分子TEM8-Fc及其在肿瘤治疗中的应用 |
| EP2637692A4 (en) * | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
| CN102875647B (zh) * | 2012-09-10 | 2014-11-19 | 上海交通大学 | 与cd40l蛋白特异性结合的配体多肽及药物输送系统 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1239866A4 (en) * | 1999-12-10 | 2005-02-09 | Epimmune Inc | INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS |
| AU2002357747A1 (en) * | 2001-12-10 | 2003-06-23 | Millennium Pharmaceuticals Inc. | Novel genes encoding colon cancer antigens |
-
2004
- 2004-11-15 US US10/579,356 patent/US20080171058A1/en not_active Abandoned
- 2004-11-15 JP JP2006539955A patent/JP2007511534A/ja active Pending
- 2004-11-15 WO PCT/US2004/038022 patent/WO2005048943A2/en not_active Ceased
- 2004-11-15 EP EP04810963A patent/EP1687432A4/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| JPN6010064030, Ｎａｉｒ，Ｓ． ｅｔ ａｌ．, "Ｓｙｎｅｒｇｙ ｂｅｔｗｅｅｎ ｔｕｍｏｒ ｉｍｍｕｎｏｔｈｅｒａｐｙ ａｎｄ ａｎｔｉａｎｇｉｏｇｅｎｉｃ ｔｈｅｒａｐｙ", Ｂｌｏｏｄ, 20030801, Ｖｏｌ．１０２，Ｎｏ．３, Ｐ．９６４−９７１ * |
| JPN6010064031, Ｃａｒｓｏｎ−Ｗａｌｔｅｒ，Ｅ．Ｂ． ｅｔ ａｌ．, "Ｃｅｌｌ ｓｕｒｆａｃｅ ｔｕｍｏｒ ｅｎｄｏｔｈｅｒｉａｌ ｍａｒｋｅｒｓ ａｒｅ ｃｏｎｓｅｒｖｅｄ ｉｎ ｍｉｃｅ ａｎｄ ｈｕｍａｎｓ", Ｃａｎｃｅ Ｒｅｓ．, 20010915, Ｖｏｌ．６１， Ｎｏ．１８, Ｐ．６６４９−６６５５ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016208988A (ja) * | 2010-10-19 | 2016-12-15 | メリアル インコーポレイテッド | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン |
| JP7256024B2 (ja) | 2013-03-15 | 2023-04-11 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ガンワクチン及びそれを用いた治療方法 |
| JP2017522326A (ja) * | 2014-07-18 | 2017-08-10 | ユニヴァーシティ オブ ワシントン | がんワクチン組成物およびその使用方法 |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1687432A2 (en) | 2006-08-09 |
| WO2005048943A2 (en) | 2005-06-02 |
| EP1687432A4 (en) | 2008-08-27 |
| WO2005048943A3 (en) | 2005-12-29 |
| US20080171058A1 (en) | 2008-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Disis et al. | HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer | |
| JP2025129169A (ja) | ガンワクチン及びそれを用いた治療方法 | |
| Tüting et al. | Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice | |
| US11266726B2 (en) | Compositions and methods for the treatment of HER2-expressing solid tumors | |
| US20210121522A1 (en) | Mixed-lineage kinase domain-like protein in immunotherapeutic cancer control | |
| CA2798837A1 (en) | Her-2 peptides and vaccines | |
| EP2456458B1 (en) | Dendritic cell vaccines for asparaginyl - beta - hydroxylase expressing tumors | |
| RU2385163C2 (ru) | Профилактическая противораковая вакцина | |
| JP2007511534A (ja) | 抗腫瘍免疫の相乗的誘導のための組成物および方法 | |
| CN101575607B (zh) | 一种基于人muc1重复序列与gm-csf融合表达的重组卡介苗疫苗 | |
| Sarobe et al. | Carcinoembryonic antigen as a target to induce anti-tumor immune responses | |
| US9636387B2 (en) | N-domain of carcinoembryonic antigen and compositions, methods and uses thereof | |
| Hipp et al. | Cancer vaccines: an update | |
| Disis et al. | Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity | |
| JP2002534478A (ja) | 絨毛性ゴナドトロピンｄｎａワクチンおよび方法 | |
| Muraro et al. | Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses | |
| EP1696950A2 (en) | Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its use for the treatment of angiogenic-related disorders | |
| JP2007505601A (ja) | ワクチン | |
| CN1966684B (zh) | 一种新的HER2/neu mRNA体外转录载体的构建及其用途 | |
| Alexeev et al. | Recombinant DNA technology in emerging modalities for melanoma immunotherapy | |
| Durrant et al. | Colorectal Tumor Immunity | |
| HK40060707B (zh) | Mrna疫苗 | |
| Sas | HER-2/neu-targeted immunoprevention of breast cancer | |
| Leslie | DNA vaccination against the novel tumor antigen, MUC18, for the therapy of metastatic melanoma | |
| HK1178935B (en) | Methods and compositions containing fc fusion proteins for enhancing immune responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110419 |